Stefan Anker

Employment

• Charité

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (1533)

• Effectiveness of finerenone in slowing chronic kidney disease progression after hospitalization for heart failure: a FIDELITY subgroup analysis
  European Journal of Heart Failure 2026 DOI: 10.1093/ejhf/xuag299
  +Save
• Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis
  European Journal of Heart Failure 2026 DOI: 10.1093/ejhf/xuag054
  +Save
• Integrated miRNA-cytokine profiling reveals a molecular signature of cachexia in patients with chronic heart failure
  ESC Heart Failure 2026 DOI: 10.1093/eschf/xvag229
  +Save
• Modeling Individual Patient Outcomes After Interatrial Shunt Treatment in Heart Failure With Reduced and Preserved Ejection Fraction: The RELIEVE-HF Trial
  Gregg W. Stone, JoAnn M. Lindenfeld, Michael R. Zile +17 more
  Circulation: Heart Failure 2026 DOI: 10.1161/CIRCHEARTFAILURE.125.014100
  +Save
• Muscle and Bone Implications of GLP‐1 Receptor Agonists and Fragility Fractures in Older Adults With Diabetes
  Journal of Cachexia, Sarcopenia and Muscle 2026 DOI: 10.1002/jcsm.70371
  +Save
• Target versus below-target dose ACE inhibitors in US veterans with HFpEF: differential outcomes by CKD status
  European Journal of Heart Failure 2026 DOI: 10.1093/ejhf/xuag237
  +Save
• Front Cover
  Diabetes, Obesity and Metabolism 2026 DOI: 10.1111/dom.70968
  +Save
• Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
  Diabetes, Obesity and Metabolism 2026 DOI: 10.1111/dom.70750
  +Save
• The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
  Nature Medicine 2026 DOI: 10.1038/s41591-026-04408-4
  +Save
• Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
  European Heart Journal 2026 DOI: 10.1093/eurheartj/ehag201
  +Save
• Adipose Tissue and Lipid Dysregulation Contributions to Cachexia, Sarcopenia and Muscle Function
  Journal of Cachexia, Sarcopenia and Muscle 2026 DOI: 10.1002/jcsm.70299
  +Save
• Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity
  Journal of Cachexia, Sarcopenia and Muscle 2026 DOI: 10.1002/jcsm.70298
  +Save
• Comparative analysis of randomized versus real-world populations in heart failure: DIAMOND trial vs CARE-HK registry
  ESC Heart Failure 2026 DOI: 10.1093/eschf/xvag155
  +Save
• Digitalis – back on centre stage for HFrEF
  Johann Bauersachs, Gianluigi Savarese, Michael Böhm +4 more
  European Journal of Heart Failure 2026 DOI: 10.1093/ejhf/xuaf002
  +Save
• Sodium glucose co-transporter inhibition as a strategy to stabilize the microvasculature in sickle cell disease
  Cardiovascular Research 2026 DOI: 10.1093/cvr/cvag055
  +Save
• Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations
  Nephrology Dialysis Transplantation 2026 DOI: 10.1093/ndt/gfaf183
  +Save
• The EMPATICC-trial—should location shape therapy?
  European Heart Journal 2026 DOI: 10.1093/eurheartj/ehag009
  +Save
• A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.
  Card Fail Rev 2026 DOI: 10.15420/cfr.2025.50
  +Save
• Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group.
  Card Fail Rev 2026 DOI: 10.15420/cfr.2025.56
  +Save
• Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.
  Int J Cardiol 2026 DOI: 10.1016/j.ijcard.2026.134637
  +Save